Piomic raises CHF 7.5M Series A round
Summary
In a multicenter, prospective, comparative clinical trial the safety and effectiveness of COMS\xae treatment was investigated in wound care excellence centers in Switzerland. Furthermore, Piomic introduced its product in selected global advanced wound care markets during an initial soft launch, receiving great customer feedback with over 5.000 treatments performed and 450 patients treated. Clinicians and nurses are impressed by the effectiveness and ease of use of COMS\xae therapy.Piomic is now initiating a large randomized controlled trial (RCT) to strengthen the body of evidence for clinical efficacy and subsequent US market clearance of COMS\xae therapy via the FDA De-Novo pathway. The MAVERICKS clinical trial focuses on the beneficial effects of COMS\xae treatment in patients suffering from therapy refractory diabetic foot ulcers. Further non-dilutive funding will be used to integrate COMS\xae therapy with telemedicine solutions to navigate the complex care-delivery system for chronic wound patients at home.